Stevanato Group S.p.A Total Long Term Liabilities 2021-2024 | STVN

Stevanato Group S.p.A total long term liabilities from 2021 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Stevanato Group S.p.A Total Long Term Liabilities 2021-2024 | STVN

Stevanato Group S.p.A total long term liabilities from 2021 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.5B
Takeda Pharmaceutical (TAK)$43.4B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.3B
Sandoz Group AG (SDZNY)$19.9B
United Therapeutics (UTHR)$17.9B
Summit Therapeutics (SMMT)$16.1B
Neurocrine Biosciences (NBIX)$12.9B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.4B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.1B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
Dyne Therapeutics (DYN)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.8B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.6B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.8B
Evotec AG (EVO)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B